DrugBiological
Bebtelovimab clinical trials
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
3 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Eli Lilly and Company (2) · Erin McCreary (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses bebtelovimab is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 IllnessCompletedPhase 2/3Eli Lilly and CompanyNCT04427501Written as LY3853113
- UPMC OPTIMISE-C19 Trial, a COVID-19 StudyTerminatedPhase 4Erin McCrearyNCT04790786Written as Bebtelovimab
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 IllnessCompletedPhase 2Eli Lilly and CompanyNCT04634409Written as Bebtelovimab
Codes
What other systems call bebtelovimab · ClinicalTrials.gg INT001615
- MeSH (NLM) C000716927bebtelovimabOne source NLM
- UNII (FDA) 8YL4SYR6CUBEBTELOVIMABConfirmed FDA, NLM
- RxNorm 2592360One source FDA
- NCI Thesaurus C182122BebtelovimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716927 | bebtelovimab | One source NLM |
| UNII (FDA) | 8YL4SYR6CU | BEBTELOVIMAB | Confirmed FDA, NLM |
| RxNorm | 2592360 | — | One source FDA |
| NCI Thesaurus | C182122 | Bebtelovimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.